{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Day', 'PET scan up to 28 days or up to', 'D1', '14 days', 'Time (hour/minute)', 'Prior dosing', 'OH', '1H', '3H', 'Safety', 'Physical examination', 'X', 'Body temperature', 'X', 'Body weight', 'X', 'Vital signs9, 12 lead-ECG', 'X', 'X', 'X', 'Hematology, biochemistry, urinalysis', 'X', 'Renal function (blood creatinine/, and', 'X', 'cystatin C)', 'Adverse event collection', '&', 'Pharmacokinetics', 'SAR407899 plasma samples', 'X', 'X', 'DNA', 'Pharmacogenetic DNA sample', 'X', 'Biomarkers', 'Blood samples for', 'and', 'X', 'Future use of samples', 'Blood sample if specific consent', 'X', 'signed', 'DME = drug metabolizing enzymes; ECG = electrocardiogram; IMP = investigational medicinal product.', 'Note: when several items take place at the same time, the following order should be respected: questionnaires, pharmacodynamics, ECG, vital signs, blood sampling, drug administration, meal.', 'In order to respect exact timing of pharmacokinetic samples, the other measures will be done ahead of the scheduled time.', 'a', 'Time (hour/minute) is expressed in reference to the first administration of SAR407899 (TOH). Prior dosing at the arrival on site, if it takes eg. 3 hours to get creatinine result after the blood sampling, to check that', 'the patients do not meet the exclusion criterion E25, vital signs and 12-lead ECG may have to be repeated closer before dosing. Otherwise, blood creatinine result may be obtained within 2 days prior to Day 1.', 'b Concomitant medication (if those are not allowed during the study, see exclusion criterion 3 in Section 7.2.1) needs to be stopped 1 week before CFR assessed by PET scan.', 'C Restriction rules for CFR assessed by vasodilator stress PET scan (detailed in Section 10.1.2) to follow.', 'Property of the Sanofi Group - strictly confidential', 'Page 19', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'd Prior to the PET assessment, the available eligibility criteria must be carefully reviewed (including review of the screening labs), and if the patient no longer qualifies for the study, then he/she should not undergo', 'the PET assessment.', 'e Refer to Safety Section 9.2 for detailed safety investigations.', 'f Vital signs should be performed by the investigator or designee. Continuous monitoring of heart rate, BP and 12-lead ECG should be performed throughout the stressor infusion.', 'g Vital signs: BP & heart rate measurements including search of hypotension (orthostatic or not).', 'h Only for PET scan.', 'i', \"The patient may be discharged later on Day 1 to guarantee patient's safety based upon the opinion of the Investigator.\", 'j', 'Mandatory before dosing to check criterion E 25.', 'k', 'To be repeated as close as possible and before to the study drug administration if the turnaround time to get the results of creatinine before dosing is approximately 3 hours.', '1.5', 'DAY 29 FLOW CHART SUGGESTED TIME FRAME (CAN BE ADAPTED BY SITE)', 'Day', 'D29', 'Time (hour/minute)', 'At arrival', 'OH Study', '1H', '2H', '3H before', 'Additional hours', 'at the site', 'drug intake', 'leaving', \"at Investigator's\", 'the site', 'discretion', 'Visit start', 'X', 'End of visit', 'x\u00b9', 'Concomitant medications', 'SAQ', 'X', \"Patients' perception of treatment and symptoms\", 'X', \"Patient's diary\", '<', 'IMP administration', 'xg', 'CFR assessed by vasodilator stress PET scanb, e', 'x', 'NIMP administration', 'x\"', 'Safety d', 'Physical examination', 'X', 'Body temperature', 'X', 'Property of the Sanofi Group - strictly confidential', 'Page 20', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}